explore -WSS

explore

author：hotspot 2025-09-28 23:11:37 - browse：6

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Kenai launches with $82 million for Parkinson’s stem cell therapy

leisure time

WSS

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Brazil's Jair Bolsonaro is barred from running for office until 2030

FDA does about

In search for therapies for solid tumors, companies turn to claudin

An inside look at PIPEs, biotech's buzzy new financing tool

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

focus

explore

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to fix the rural physician shortage in the U.S.

Hepatitis C has a cure — but many Americans still lack access to it

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Tori Bowie and the unacceptable rates of Black maternal death

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Cancer drug shortages should be causing more outrage

Change Healthcare cyberattack outage could last weeks

focus

GOP inquiry over gain

Covid isolation guidance eased by the CDC

The simple reason for the increase in autism diagnosis

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Biotech companies concerned about China biosecurity crackdown

hotspot

focus

leisure time

hotspot